Health Care Delivery

Latest News

August 3rd 2016

What We're Reading: More Than Half of Hospitals Will Be Penalized for Readmissions

What we're reading, August 3, 2016: Medicare penalties for hospital readmissions reach a new high; the importance of down-ballot races this election; and Virginia's Bureau of Insurance comes out against the Anthem-Cigna merger.

August 2nd 2016

What We're Reading: 2 More Co-Ops Sue Obama Administration

By AJMC Staff

August 1st 2016

Evolving Expectations of Consumers on the ACA's Exchanges

By Laura Joszt, MA

August 1st 2016

What We're Reading: Colorado Asks Sanders to Help With Its Universal Healthcare Proposal

By AJMC Staff

July 31st 2016

Dr Joe Antos on the American Enterprise Institute's ACA Proposals

The Value of Patient Assistance Programs

July 28th 2016

Do Accelerated Review and Narrow Indications Influence Payer Decisions?

July 28th 2016

Clinical Pathways

July 28th 2016

Appropriate Use of Companion Versus Complementary Diagnostics

July 28th 2016

Influence of Biomarkers in Immunotherapy Treatment Decisions

July 28th 2016

Payer Stance on Immunotherapy in Oncology Care

July 28th 2016

Importance of Patient Assistance Programs in Oncology

July 28th 2016

Do Oncologists Contemplate Patient Cost Sharing?

July 28th 2016

Value Benchmarks in Immuno-Oncology

July 28th 2016

The Unmet Need in Immuno-Oncology and New Drug Approvals

July 28th 2016

Health Plan Take on the Cancer Drug Approval Process and Surrogate Endpoints

July 28th 2016

Improving Patient Access-Rapid Approval and Patient Assistance Programs

July 28th 2016

Combination Therapies: What Works Best for Immuno-Oncology?

July 28th 2016

Payer Concerns With Including Novel Immunotherapies on Clinical Pathways

July 28th 2016

Combination Immunotherapies in Melanoma

July 28th 2016

Understanding Immunotherapy Efficacy and Safety

July 28th 2016

Clinical Pathway Consideration and Payer Decisions

July 28th 2016

Safety and Efficacy of Targeted Therapy Versus Immunotherapy in Melanoma

July 28th 2016

Clinician Concerns with Adopting Clinical Pathways

July 28th 2016

Health Plan Perspectives on Clinical Pathways

July 28th 2016

Clinical Pathways Should Keep Pace With New Data

July 28th 2016

Distinguishing Between Companion and Complementary Diagnostic Tests

July 28th 2016

Health Plan Coverage of Diagnostic Tests for PD-L1 Expression

July 28th 2016

Predictive Biomarker Testing for Immunotherapy in Melanoma

July 28th 2016

How Important Are Biomarkers for Treatment Selection in Lung Cancer?

July 28th 2016

Health Care Delivery

Latest News

The Value of Patient Assistance Programs

Do Accelerated Review and Narrow Indications Influence Payer Decisions?

Clinical Pathways

Appropriate Use of Companion Versus Complementary Diagnostics

Influence of Biomarkers in Immunotherapy Treatment Decisions

Payer Stance on Immunotherapy in Oncology Care

Importance of Patient Assistance Programs in Oncology

Do Oncologists Contemplate Patient Cost Sharing?

Value Benchmarks in Immuno-Oncology

The Unmet Need in Immuno-Oncology and New Drug Approvals

Health Plan Take on the Cancer Drug Approval Process and Surrogate Endpoints

Improving Patient Access-Rapid Approval and Patient Assistance Programs

Combination Therapies: What Works Best for Immuno-Oncology?

Payer Concerns With Including Novel Immunotherapies on Clinical Pathways

Combination Immunotherapies in Melanoma

Understanding Immunotherapy Efficacy and Safety

Clinical Pathway Consideration and Payer Decisions

Safety and Efficacy of Targeted Therapy Versus Immunotherapy in Melanoma

Clinician Concerns with Adopting Clinical Pathways

Health Plan Perspectives on Clinical Pathways

Clinical Pathways Should Keep Pace With New Data

Distinguishing Between Companion and Complementary Diagnostic Tests

Health Plan Coverage of Diagnostic Tests for PD-L1 Expression

Predictive Biomarker Testing for Immunotherapy in Melanoma

How Important Are Biomarkers for Treatment Selection in Lung Cancer?

Trending on AJMC

FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301

New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease

Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship

Odronextamab Plus CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Matthew Matasar, MD

New French Psoriasis Guidelines Add Biologics, Comorbidity Guidance to Algorithm